J 2016

Role of substance P in the cardiovascular system

MISTROVA, Eliska; Peter KRUŽLIAK a Magdalena DVORAKOVA CHOTTOVA

Základní údaje

Originální název

Role of substance P in the cardiovascular system

Autoři

MISTROVA, Eliska; Peter KRUŽLIAK a Magdalena DVORAKOVA CHOTTOVA

Vydání

NEUROPEPTIDES, EDINBURGH, CHURCHILL LIVINGSTONE, 2016, 0143-4179

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30202 Endocrinology and metabolism

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.486

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/16:00100473

Organizační jednotka

Lékařská fakulta

EID Scopus

Klíčová slova anglicky

Substance P; NK1 receptor; Cardiovascular regulation; Antagonist

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 11. 5. 2018 15:16, Soňa Böhmová

Anotace

V originále

This article provides an overview of the structure and function of substance P signalling system and its involvement in the cardiovascular regulation. Substance P is an undecapeptide originating from TAC1 gen and belonging to the tachykinin family. The biological actions of substance P are mainly mediated through neurokinin receptor 1 since substance P is the ligand with the highest affinity to neurokinin receptor 1. Substance P is widely distributed within the central and peripheral nervous systems as well as in the cardiovascular system. Substance P is involved in the regulation of heart frequency, blood pressure and in the stretching of vessels. Substance P plays an important role in ischemia and reperfusion and cardiovascular response to stress. Additionally, it has been also implicated in angiogenesis, pain transmission and inflammation. The substance P/neurokinin receptor 1 receptor system is involved in the molecular bases of many human pathological processes. Antagonists of neurokinin receptor 1 receptor could provide clinical solutions for a variety of diseases. Neurokinin receptor 1 antagonists are already used in the prevention of chemotherapy induced nausea and vomiting. (C) 2015 Elsevier Ltd. All rights reserved.